摘要
目的探讨18F-FDG PET/CT在淋巴瘤初始分期中评估脾脏受累的最佳方法。方法回顾59例淋巴瘤患者治疗前初始分期的18F-FDG PET/CT结果,采用脾脏肋单元计数(简称肋单元)、脾指数、脾内结节灶、脾脏最大标准摄取值(SUVmax)及目测脾内18F-FDG高摄取(简称PET目测法)评估脾脏是否受累,并与随访确诊结果进行一致性检验。结果59例中,最终确诊初始分期中21例脾脏受累(阳性组),38例无脾脏受累(阴性组),两组肋单元(t=4.670,P<0.0001)、脾指数(t=4.688,P=0.0001)及SUVmax(t=4.971,P=0.0001)差异均有统计学意义;阳性组脾结节发生率和PET目测法明显高于阴性组(χ2=23.395、54.750,P均<0.0001)。根据肋单元、脾结节、脾指数、SUVmax、PET目测法评估脾脏受累的Kappa值分别为0.494、0.596、0.704、0.787、0.963。结论淋巴瘤治疗前初始分期中,目测脾内存在局灶性或弥漫性异常18F-FDG高摄取是评估脾脏受累的最佳方法。
Objective To observe the best approach for noninvasive evaluation on the splenic involvement during initial staging of lymphoma with 18F-FDG PET/CT. Methods Retrospective analysis was performed on 59 patients with proven lymphoma who underwent 18F-FDG PET/CT for evaluating splenic involvement of lymphoma before treatment. Noninvasive approach were used, including splenic rib-unit （SRU）, splenic index （SI）, splenic nodules （SN） and the maximum standardized uptake value in spleen （SUVmax） as well as while visually assessment （VA） on PET imaging, and consistence test was performed with follow-up results, respectively. Result Of 59 cases of lymphoma, there were 21 with true splenic involvement （positive group）, while 38 patients were found without splenic involvement （negative group）. Statistical differences in SRU （t=4.670, P〈0.0001）, SI （t=4.688, P=0.0001） and SUVmax （t=4.971, P=0.0001） were found between the two groups. SN and VA in positive group were higher than those in negative group （χ2=23.395, 54.750, all P〈0.0001）. Kappa value was 0.494 for SRU, 0.704 for SI, 0.596 for SN, 0.787 for SUVmax, and 0.963 for VA compared with the gold standards, respectively. Conclusion During initial staging of lymphoma with 18F-FDG PET/CT before treatment, VA is the best approach for noninvasive evaluating on splenic involvement of lymphoma.
出处
《中国医学影像技术》
CSCD
北大核心
2014年第3期411-415,共5页
Chinese Journal of Medical Imaging Technology
